Select a Region North America


Rohit Sood

Executive Vice President, COMPLETE Commercialization


Brand Plan Development, Commercialization, Digital Medicine, Forecasting Activities, HEOR, Leadership, Management, Market Access, Oncology, Operational Transformation, Patient Journey, Product Launch, Project Management, Rare Disease

Rohit is helping EVERSANA disrupt the life sciences industry with innovative commercialization solutions. As a strategy and operations professional, he has served as both an advisor and global strategy leader, driving top-line business growth and identifying significant operational efficiencies in PE-backed, startup and publicly listed organizations. He has advised senior management and CEOs of global life sciences companies on critical topics, including therapeutic area growth strategy, R & D, licensing, go-to-market approaches, launch/commercial excellence and commercial models.

Rohit holds an MBA from Rutgers Business School and an MS in telecommunications from Pace University.

Articles by Rohit Sood

WEBINAR: A Pivotal Shift in Life Sciences Industry Across R&D and Commercial: A Conversation with the Experts

The life sciences pipeline is evolving from small molecules to biologics and cell and gene therapy, and there are currently more than 900 therapies in clinical trials. As competition rises, manufacturers also need to manage the reality that the cost of research and development has doubled as ROI reduces from 10% to 2%. In this […]

Webinar: Next Generation Commercial Innovation: Moving from Promise to Practice

As pharma continues to evolve, commercialization models must evolve also. In this PharmaVOICE webinar, EVERSANA’s Rohit Sood, EVP, COMPLETE Commercialization, and Resverlogix’s CEO Donald J. McCaffrey discuss why pharma companies are focusing on new commercial models that are agile and built on operational excellence and renewable infrastructure to recognize resource and cost benefit.  While “innovative” […]

CHALLENGING TRADITION: The argument for integrated commercialization to improve operational agility

Today’s economics simply do not support building commercial capabilities from scratch, only to dismantle that infrastructure until the next need arrives. Manufacturers will spend approximately $200 million of commercialization costs over three years leading up to the launch of their product, yet 66% of drugs do not meet launch expectations.    In an era of specialty and […]

Interested in scheduling a meeting or speaking event?

Contact Us

  • This field is for validation purposes and should be left unchanged.